5-Methoxypsoralen increases evening sleepiness in humans: possible involvement of the melatonin secretion.
The acute and short-term effect of 5-methoxypsoralen (5-MOP) on daytime sleepiness was investigated in 12 healthy subjects according to a double-blind cross-over design. 5-MOP (40 mg/day) or placebo was orally administered (one week each) at 16.00 h. 5-MOP significantly increases daytime sleepiness 4 to 5 h after administration without affecting the subsequent sleep efficiency and duration. We found a positive correlation between sleepiness and melatonin levels. Our findings suggest that the melatonin secretion may play a role in the effect of 5-MOP on sleepiness in humans.
Souêtre
E
E
Clinique de psychiatrie et de psychologie médicale, Hôpital Pasteur, Nice, France.
Salvati
E
E
Belugou
J L
JL
Krebs
B
B
Darcourt
G
G
D000078223:5-Methoxypsoralen; D000328:Adult; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008550:Melatonin / Q000097:blood / Q000378:metabolism*; D008730:Methoxsalen / Q000009:adverse effects / Q000494:pharmacology*; D012890:Sleep; D012894:Sleep Stages / Q000187:drug effects*; D013997:Time Factors
D000078223:5-Methoxypsoralen; D008550:Melatonin; D008730:Methoxsalen